Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine

Autores
Brenta, Gabriela; Berg, Gabriela Alicia; Miksztowicz, Verónica Julieta; Lopez, Graciela Ines; Lucero, Diego Martín; Faingold, María Cristina; Murakami, Masami; Machima, Tetsudo; Nakajima, Katsuyuki; Schreier, Laura Ester
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Qualitative lipoprotein changes, such as an increase in fasting remnants, are reported in subclinical hypothyroidism (SCH). It was hypothesized that such changes are due to reduced hepatic lipase (HL) activity in SCH: HL is an enzyme regulated by thyroid hormones, and is involved in the degradation of triglyceride (TG)-rich remnants. This study aimed to quantify remnant-like lipoproteins (RLP), small dense LDL (sdLDL), and HL activity in women with SCH, and to assess these parameters after levothyroxine replacement therapy. Methods: This was an observational cross-sectional study with a subsequent longitudinal follow-up. Findings in women with thyrotropin levels >4.5 mIU/L (SH group) were compared with age- and body mass index (BMI)-matched euthyroid women (control group). In addition, a subgroup analysis was undertaken in SCH women who chose to receive levothyroxine treatment (0.9 μg/kg/day) for 6 months. RLP was quantified by measuring cholesterol (RLP-C) and triglycerides (RLP-TG) after immunoaffinity chromatography, and sdLDL by automated standardized methods; HL activity was measured in post-heparin plasma. Results: The SCH group included 37 women; 29 women were included in the control group. In addition, 22 women with SCH were included in the subgroup analysis (levothyroxine treatment). Significantly higher RLP values were observed in the SCH group than in the control group: RLP-C (median [range], mg/dL): 20.3 (5.8-66.8) versus 10.2 (2.7-36.3), p = 0.005; RLP-TG (mg/dL): 26.3 (3.2-123.3) versus 12.1 (2.5-61.6), p = 0.033. HL activity (mean ± standard deviation [SD], μmol free fatty acid/mL post-heparin plasma.h) - 9.83 ± 4.25 versus 9.92 ± 5.20, p = 0.707 - and sdLDL levels (mg/dL) - 23.1 ± 10.7 versus 22.6 ± 8.4, p = 0.83 - were similar. After levothyroxine, RLP-C decreased - 21.5 (5.8-66.8) versus 17.2 (4.1-45.6), p = 0.023 - and HL increased - 9.75 ± 4.04 versus 11.86 ± 4.58, p = 0.012 - in the subgroup of SCH women. No changes in sdLDL were observed. Conclusions: Women with SCH have higher RLP levels than matched controls do, but their RLP-C levels decrease significantly following levothyroxine therapy. Furthermore, HL activity also increases after levothyroxine therapy and can be interpreted as a possible explanation for the decrease in RLP-C.
Fil: Brenta, Gabriela. Unidad Asistencial Doctor César Milstein; Argentina
Fil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lopez, Graciela Ines. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lucero, Diego Martín. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Faingold, María Cristina. Unidad Asistencial Doctor César Milstein; Argentina
Fil: Murakami, Masami. Gunma University Graduate School Of Medicine; Japón
Fil: Machima, Tetsudo. Gunma University Graduate School Of Medicine; Japón
Fil: Nakajima, Katsuyuki. Graduate School Of Health Sciences, Gunma University; Japón
Fil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
Lipoproteins
Subclinical Hypothyroidism
Hepatic Lipase Activity
Cardiovascular Risk
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/39313
Acceder
id CONICETDig_d0b1c50336a35aef165413b9c1c76280
oai_identifier_str oai:ri.conicet.gov.ar:11336/39313
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxineBrenta, GabrielaBerg, Gabriela AliciaMiksztowicz, Verónica JulietaLopez, Graciela InesLucero, Diego MartínFaingold, María CristinaMurakami, MasamiMachima, TetsudoNakajima, KatsuyukiSchreier, Laura EsterLipoproteinsSubclinical HypothyroidismHepatic Lipase ActivityCardiovascular Riskhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Qualitative lipoprotein changes, such as an increase in fasting remnants, are reported in subclinical hypothyroidism (SCH). It was hypothesized that such changes are due to reduced hepatic lipase (HL) activity in SCH: HL is an enzyme regulated by thyroid hormones, and is involved in the degradation of triglyceride (TG)-rich remnants. This study aimed to quantify remnant-like lipoproteins (RLP), small dense LDL (sdLDL), and HL activity in women with SCH, and to assess these parameters after levothyroxine replacement therapy. Methods: This was an observational cross-sectional study with a subsequent longitudinal follow-up. Findings in women with thyrotropin levels >4.5 mIU/L (SH group) were compared with age- and body mass index (BMI)-matched euthyroid women (control group). In addition, a subgroup analysis was undertaken in SCH women who chose to receive levothyroxine treatment (0.9 μg/kg/day) for 6 months. RLP was quantified by measuring cholesterol (RLP-C) and triglycerides (RLP-TG) after immunoaffinity chromatography, and sdLDL by automated standardized methods; HL activity was measured in post-heparin plasma. Results: The SCH group included 37 women; 29 women were included in the control group. In addition, 22 women with SCH were included in the subgroup analysis (levothyroxine treatment). Significantly higher RLP values were observed in the SCH group than in the control group: RLP-C (median [range], mg/dL): 20.3 (5.8-66.8) versus 10.2 (2.7-36.3), p = 0.005; RLP-TG (mg/dL): 26.3 (3.2-123.3) versus 12.1 (2.5-61.6), p = 0.033. HL activity (mean ± standard deviation [SD], μmol free fatty acid/mL post-heparin plasma.h) - 9.83 ± 4.25 versus 9.92 ± 5.20, p = 0.707 - and sdLDL levels (mg/dL) - 23.1 ± 10.7 versus 22.6 ± 8.4, p = 0.83 - were similar. After levothyroxine, RLP-C decreased - 21.5 (5.8-66.8) versus 17.2 (4.1-45.6), p = 0.023 - and HL increased - 9.75 ± 4.04 versus 11.86 ± 4.58, p = 0.012 - in the subgroup of SCH women. No changes in sdLDL were observed. Conclusions: Women with SCH have higher RLP levels than matched controls do, but their RLP-C levels decrease significantly following levothyroxine therapy. Furthermore, HL activity also increases after levothyroxine therapy and can be interpreted as a possible explanation for the decrease in RLP-C.Fil: Brenta, Gabriela. Unidad Asistencial Doctor César Milstein; ArgentinaFil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Lopez, Graciela Ines. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Lucero, Diego Martín. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Faingold, María Cristina. Unidad Asistencial Doctor César Milstein; ArgentinaFil: Murakami, Masami. Gunma University Graduate School Of Medicine; JapónFil: Machima, Tetsudo. Gunma University Graduate School Of Medicine; JapónFil: Nakajima, Katsuyuki. Graduate School Of Health Sciences, Gunma University; JapónFil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMary Ann Liebert2016-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/39313Brenta, Gabriela; Berg, Gabriela Alicia; Miksztowicz, Verónica Julieta; Lopez, Graciela Ines; Lucero, Diego Martín; et al.; Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine; Mary Ann Liebert; Thyroid; 26; 3; 3-2016; 365-3721050-7256CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1089/thy.2015.0140info:eu-repo/semantics/altIdentifier/url/https://www.liebertpub.com/doi/10.1089/thy.2015.0140info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:02:05Zoai:ri.conicet.gov.ar:11336/39313instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:02:05.431CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
title Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
spellingShingle Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
Brenta, Gabriela
Lipoproteins
Subclinical Hypothyroidism
Hepatic Lipase Activity
Cardiovascular Risk
title_short Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
title_full Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
title_fullStr Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
title_full_unstemmed Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
title_sort Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine
dc.creator.none.fl_str_mv Brenta, Gabriela
Berg, Gabriela Alicia
Miksztowicz, Verónica Julieta
Lopez, Graciela Ines
Lucero, Diego Martín
Faingold, María Cristina
Murakami, Masami
Machima, Tetsudo
Nakajima, Katsuyuki
Schreier, Laura Ester
author Brenta, Gabriela
author_facet Brenta, Gabriela
Berg, Gabriela Alicia
Miksztowicz, Verónica Julieta
Lopez, Graciela Ines
Lucero, Diego Martín
Faingold, María Cristina
Murakami, Masami
Machima, Tetsudo
Nakajima, Katsuyuki
Schreier, Laura Ester
author_role author
author2 Berg, Gabriela Alicia
Miksztowicz, Verónica Julieta
Lopez, Graciela Ines
Lucero, Diego Martín
Faingold, María Cristina
Murakami, Masami
Machima, Tetsudo
Nakajima, Katsuyuki
Schreier, Laura Ester
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Lipoproteins
Subclinical Hypothyroidism
Hepatic Lipase Activity
Cardiovascular Risk
topic Lipoproteins
Subclinical Hypothyroidism
Hepatic Lipase Activity
Cardiovascular Risk
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Qualitative lipoprotein changes, such as an increase in fasting remnants, are reported in subclinical hypothyroidism (SCH). It was hypothesized that such changes are due to reduced hepatic lipase (HL) activity in SCH: HL is an enzyme regulated by thyroid hormones, and is involved in the degradation of triglyceride (TG)-rich remnants. This study aimed to quantify remnant-like lipoproteins (RLP), small dense LDL (sdLDL), and HL activity in women with SCH, and to assess these parameters after levothyroxine replacement therapy. Methods: This was an observational cross-sectional study with a subsequent longitudinal follow-up. Findings in women with thyrotropin levels >4.5 mIU/L (SH group) were compared with age- and body mass index (BMI)-matched euthyroid women (control group). In addition, a subgroup analysis was undertaken in SCH women who chose to receive levothyroxine treatment (0.9 μg/kg/day) for 6 months. RLP was quantified by measuring cholesterol (RLP-C) and triglycerides (RLP-TG) after immunoaffinity chromatography, and sdLDL by automated standardized methods; HL activity was measured in post-heparin plasma. Results: The SCH group included 37 women; 29 women were included in the control group. In addition, 22 women with SCH were included in the subgroup analysis (levothyroxine treatment). Significantly higher RLP values were observed in the SCH group than in the control group: RLP-C (median [range], mg/dL): 20.3 (5.8-66.8) versus 10.2 (2.7-36.3), p = 0.005; RLP-TG (mg/dL): 26.3 (3.2-123.3) versus 12.1 (2.5-61.6), p = 0.033. HL activity (mean ± standard deviation [SD], μmol free fatty acid/mL post-heparin plasma.h) - 9.83 ± 4.25 versus 9.92 ± 5.20, p = 0.707 - and sdLDL levels (mg/dL) - 23.1 ± 10.7 versus 22.6 ± 8.4, p = 0.83 - were similar. After levothyroxine, RLP-C decreased - 21.5 (5.8-66.8) versus 17.2 (4.1-45.6), p = 0.023 - and HL increased - 9.75 ± 4.04 versus 11.86 ± 4.58, p = 0.012 - in the subgroup of SCH women. No changes in sdLDL were observed. Conclusions: Women with SCH have higher RLP levels than matched controls do, but their RLP-C levels decrease significantly following levothyroxine therapy. Furthermore, HL activity also increases after levothyroxine therapy and can be interpreted as a possible explanation for the decrease in RLP-C.
Fil: Brenta, Gabriela. Unidad Asistencial Doctor César Milstein; Argentina
Fil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lopez, Graciela Ines. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lucero, Diego Martín. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Faingold, María Cristina. Unidad Asistencial Doctor César Milstein; Argentina
Fil: Murakami, Masami. Gunma University Graduate School Of Medicine; Japón
Fil: Machima, Tetsudo. Gunma University Graduate School Of Medicine; Japón
Fil: Nakajima, Katsuyuki. Graduate School Of Health Sciences, Gunma University; Japón
Fil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Background: Qualitative lipoprotein changes, such as an increase in fasting remnants, are reported in subclinical hypothyroidism (SCH). It was hypothesized that such changes are due to reduced hepatic lipase (HL) activity in SCH: HL is an enzyme regulated by thyroid hormones, and is involved in the degradation of triglyceride (TG)-rich remnants. This study aimed to quantify remnant-like lipoproteins (RLP), small dense LDL (sdLDL), and HL activity in women with SCH, and to assess these parameters after levothyroxine replacement therapy. Methods: This was an observational cross-sectional study with a subsequent longitudinal follow-up. Findings in women with thyrotropin levels >4.5 mIU/L (SH group) were compared with age- and body mass index (BMI)-matched euthyroid women (control group). In addition, a subgroup analysis was undertaken in SCH women who chose to receive levothyroxine treatment (0.9 μg/kg/day) for 6 months. RLP was quantified by measuring cholesterol (RLP-C) and triglycerides (RLP-TG) after immunoaffinity chromatography, and sdLDL by automated standardized methods; HL activity was measured in post-heparin plasma. Results: The SCH group included 37 women; 29 women were included in the control group. In addition, 22 women with SCH were included in the subgroup analysis (levothyroxine treatment). Significantly higher RLP values were observed in the SCH group than in the control group: RLP-C (median [range], mg/dL): 20.3 (5.8-66.8) versus 10.2 (2.7-36.3), p = 0.005; RLP-TG (mg/dL): 26.3 (3.2-123.3) versus 12.1 (2.5-61.6), p = 0.033. HL activity (mean ± standard deviation [SD], μmol free fatty acid/mL post-heparin plasma.h) - 9.83 ± 4.25 versus 9.92 ± 5.20, p = 0.707 - and sdLDL levels (mg/dL) - 23.1 ± 10.7 versus 22.6 ± 8.4, p = 0.83 - were similar. After levothyroxine, RLP-C decreased - 21.5 (5.8-66.8) versus 17.2 (4.1-45.6), p = 0.023 - and HL increased - 9.75 ± 4.04 versus 11.86 ± 4.58, p = 0.012 - in the subgroup of SCH women. No changes in sdLDL were observed. Conclusions: Women with SCH have higher RLP levels than matched controls do, but their RLP-C levels decrease significantly following levothyroxine therapy. Furthermore, HL activity also increases after levothyroxine therapy and can be interpreted as a possible explanation for the decrease in RLP-C.
publishDate 2016
dc.date.none.fl_str_mv 2016-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/39313
Brenta, Gabriela; Berg, Gabriela Alicia; Miksztowicz, Verónica Julieta; Lopez, Graciela Ines; Lucero, Diego Martín; et al.; Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine; Mary Ann Liebert; Thyroid; 26; 3; 3-2016; 365-372
1050-7256
CONICET Digital
CONICET
url http://hdl.handle.net/11336/39313
identifier_str_mv Brenta, Gabriela; Berg, Gabriela Alicia; Miksztowicz, Verónica Julieta; Lopez, Graciela Ines; Lucero, Diego Martín; et al.; Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: Response to replacement treatment with levothyroxine; Mary Ann Liebert; Thyroid; 26; 3; 3-2016; 365-372
1050-7256
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1089/thy.2015.0140
info:eu-repo/semantics/altIdentifier/url/https://www.liebertpub.com/doi/10.1089/thy.2015.0140
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Mary Ann Liebert
publisher.none.fl_str_mv Mary Ann Liebert
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269736170160128
score 13.13397

Publicaciones similares